Project Grant K23AI185322
Award Date
8/8/24
Completion Date
7/31/29
Dollars Obligated
$158K
Federal Agency
National Institute of Allergy and Infectious Diseases
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
Birmingham, AL 35294, USA
Similar Awards
This is a Project Grant awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research Program (CFDA 93.855). The grant aims to explore the impact of gender-affirming hormone therapy on HIV viral dynamics and immune responses in transgender women. The $2,314,470 award will fund research over a 5-year period from November 2024 to October 2029. The principal investigator is leveraging two cohorts of transgender women, including a...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $534,242.00 to the New York Blood Center, Inc. to study the immune and behavioral responses of transgender women to the updated seasonal COVID-19 vaccines. The goal is to understand the impact of gender-affirming hormone therapy on immune responses and use this information to improve COVID-19 vaccine uptake...
This $643,614 Project Grant awarded by the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) will fund research to investigate how testosterone modulates Staphylococcus aureus signaling and pathogenesis. The University of Texas Southwestern Medical Center is the primary awardee, and they will collaborate with researchers at the University of Colorado-Denver on aspects of the project. Key objectives include: Determining the mechanism by...
This Project Grant award from the Agency for Healthcare Research and Quality (AHRQ) under the Research on Healthcare Costs, Quality and Outcomes (CFDA 93.226) program will fund the development and evaluation of an online contraception decision aid, titled "ContraceptionForAll", for transgender and gender-nonconforming (TGNC) individuals assigned female at birth (AFAB). The $391,458 award will be used to: (1) engage TGNC AFAB individuals in participatory design to enhance an existing...
This $2,345,463 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) will fund a randomized, directly observed therapy (DOT) study to interpret clinical trials of doxycycline post-exposure prophylaxis (Doxy-PEP) for bacterial sexually transmitted infections (STIs). The study aims to develop in-depth adherence measurement techniques for doxycycline, establish dosing thresholds in hair,...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $483,000.00 to Case Western Reserve University to conduct research on defining the role of single-cell heterogeneity in bacterial vaginosis (BV). The overarching goal is to identify aspects of diversity that impact BV and provide insights into new strategies for prevention, treatment, and diagnosis. The...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) provides $392,904 to the University of Rochester to investigate the influence of the cervicovaginal phageome (bacteriophage communities) on women's reproductive health, particularly for women living with HIV/AIDS. The overarching objectives are to: 1) Characterize the cervicovaginal phageome communities over time, 2) Examine the impact of HIV/AIDS and...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $153,568 to the University of California, Los Angeles (UCLA) to conduct research on the role of interferon epsilon (IFNε) in the immune response against the protozoan parasite Trichomonas vaginalis. The research aims to: 1) determine which steps in the IFNε-mediated type I interferon response are blocked by...
The U.S. National Institute of Allergy and Infectious Diseases (NIAID) awarded a $1,564,570 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to The General Hospital Corporation (doing business as Massachusetts General Hospital) to conduct research on identifying drivers of genital inflammation and HIV acquisition in women living in sub-Saharan Africa. The project will run from August 2024 through June 2029. The grant supports several key products and...
This federal Project Grant award from the National Institutes of Health (NIH) Allergy and Infectious Diseases Research program (CFDA 93.855) supports research to investigate the role of chromosomal aberrations, specifically the loss of the Y chromosome (LOY), in driving HIV-1 latency and reactivation resistance. The $424,254 award, with an end date of July 31, 2024, will enable the University of Alabama at Birmingham (UAB) to extend their previous studies on the correlation between LOY and the...